PROJECT PLAN: PATIENT TREATMENTPROJECT PLAN: PATIENT TREATMENTWITH HIV AND HEPATITIES B VIRUSWITH HIV AND HEPATITIES B VIRUS
LUIS ANTONIO DA SILVA
reverence :reverence :“FROM GOD AND “FROM GOD AND TO GOD”TO GOD”
PROCESS OF THE REDUCTION LOG OF PATHOGENICS
BACTERIAS AND VIRUS IN HUMAN BLOOD USING HD OR
OTHER THERAPIES IMPROVEMENTS
OBJECTIVE : Increase to alive expectative for
patient soriun positive
AUTHOR: Luis Antonio da SilvaMail : [email protected] : http://br.linkedin.com/in/luissilvamanagementPhone mobil : + 55 62 99178508
PROJECT PLAN: PATIENT TREATMENTPROJECT PLAN: PATIENT TREATMENTWITH HIV AND HEPATITIES B VIRUSWITH HIV AND HEPATITIES B VIRUS
LUIS ANTONIO DA SILVA
PROJECT PLAN:PROJECT PLAN: Over :
PATIENT TREATMENT WITH HIV AND HEPATITIES B VIRUS
AUTHORAUTHOR:: LUIS ANTONIO DA SILVA
DATEDATE:: ( Presented in24th AUGUST, 1992- In Campinas
University - Brasil)
PROJECT PLAN: PATIENT TREATMENTPROJECT PLAN: PATIENT TREATMENTWITH HIV AND HEPATITIES B VIRUSWITH HIV AND HEPATITIES B VIRUS
LUIS ANTONIO DA SILVA
OBJECTIVESOBJECTIVES From a biotechnological process to be developed,
find a way and viability of HIV virus reduction in soriun positive patients.
The study involves to follow the reduction HIV virus index with the conditions above.
The study also can be done in soriun positive patients with hepatities B virus or Pathogenics bacterias.
IN SPECIFIC CASE OF HIV VIRUS, GET FOLLOWING THE “OVERLIFE” OF THE SORIUN POSITIVE PATIENTS.
PROJECT PLAN: PATIENT TREATMENTPROJECT PLAN: PATIENT TREATMENTWITH HIV AND HEPATITIES B VIRUSWITH HIV AND HEPATITIES B VIRUS
LUIS ANTONIO DA SILVA
PROCESS RESUMEPROCESS RESUME
The process consists in a blood human heating out of body at the temperature limit of the blood, with sodium chlorine solution 0.9 % increased and/or dialite treatment and finally cooling the blood in a normal temperature to re-infuse in the human organism.
PROJECT PLAN: PATIENT TREATMENTPROJECT PLAN: PATIENT TREATMENTWITH HIV AND HEPATITIES B VIRUSWITH HIV AND HEPATITIES B VIRUS
LUIS ANTONIO DA SILVA
COMMENTSCOMMENTS did did in August 92 in August 92
1. Every studies of blood heating were done in a static system or storages.
2. About infusion of sodium chlorine 0.9 % it didn´t find anything indicative in dynamic system.
3. It is unknown the dynamic behavior of the blood out of body in conditions of 54º C with sodium chlorine solution 0.9 % and get back into the human body, however in a static system there are many studies from this behavior.
PROJECT PLAN: PATIENT TREATMENTPROJECT PLAN: PATIENT TREATMENTWITH HIV AND HEPATITIES B VIRUSWITH HIV AND HEPATITIES B VIRUS
LUIS ANTONIO DA SILVA
As an observation for item no. 2, we suggest as a simple case of the patients in hemodialise treatment, for the beginning of the studies:
Hemodialise total time – 2.5 hours To be studied the temperature (initial suggestion
37º C), and total time to remain this temperature.
4. In this treatment proposed above, we don´t know how would be the patient´s behavior with their “overlife” if they would be treated several times, (for example in renal patients under hemodialise treatment) in special machines under restrict control that:
Infusion of sodium chlorine 0.9 % Heating the blood after “x” time under “x”
degrees. Cooling the blood. Remove the excessive sodium chlorine 0.9 %
PROJECT PLAN: PATIENT TREATMENTPROJECT PLAN: PATIENT TREATMENTWITH HIV AND HEPATITIES B VIRUSWITH HIV AND HEPATITIES B VIRUS
LUIS ANTONIO DA SILVA
HIVHIV VIRUS DATAVIRUS DATA
LITERATURE AND STUDIES:
A. At 54º to 56º C remained for 20 minutes there is a 1 LG10 T CID50 reduction.
B. Complete inactivation of 7 LG T CID50 between 11 and 15 days under 36 to 37º C.
C. At 54 and 56º C was seeing different kinds of reduction from HIV virus under the following times:
As indicates on item “A” above. 3 LG10 T CID50 after 1 hour. 6 LG10 T CID50 or more after 3 hours. 7 LG10 T CID50 after 5 hours, no virus detected.
NOTE: There isn´t any studies with temperature between 37 and 40º C on a timing.
PROJECT PLAN: PATIENT TREATMENTPROJECT PLAN: PATIENT TREATMENTWITH HIV AND HEPATITIES B VIRUSWITH HIV AND HEPATITIES B VIRUS
LUIS ANTONIO DA SILVA
BLOOD CARACTERISTICS AND BEHAVIORBLOOD CARACTERISTICS AND BEHAVIOR
In bibliografies are indicated the maximum temperatures blood can resist out of body. In these cases in blood bag without suffer any changes or decompose in its vital components:A.Under 40º C- (no timing indicated) with mouse red
cells were done heating studies under 38º C for 4 hours, with normal survivor results and T50CR of 10D.
B.There are studies to infunded sodium chlorine 0.9 % in the blood at 70º C – for two weeks. It can be done an infusion and after cooling using a
little separator device (4c 2243 fewwall plasma transfer set).
PROJECT PLAN: PATIENT TREATMENTPROJECT PLAN: PATIENT TREATMENTWITH HIV AND HEPATITIES B VIRUSWITH HIV AND HEPATITIES B VIRUS
LUIS ANTONIO DA SILVA
ALTERNATIVE PROPOSALALTERNATIVE PROPOSAL(UNDER COMPARISON STUDIES)...(UNDER COMPARISON STUDIES)...
1. Development of the heat blood process in hemodialise machine , also the best design for the heat exchange system and pumping; to be evaluated: Timing and Temperatures.
2. In this case, the device must permit a higher range of the blood remaining under heating, according the temperature required.
CAUTION: All components of the system must be evaluated to not create blood hemolisys.
PROJECT PLAN: PATIENT TREATMENTPROJECT PLAN: PATIENT TREATMENTWITH HIV AND HEPATITIES B VIRUSWITH HIV AND HEPATITIES B VIRUS
LUIS ANTONIO DA SILVA
...ALTERNATIVE PROPOSAL...ALTERNATIVE PROPOSAL(UNDER COMPARISON STUDIES)(UNDER COMPARISON STUDIES)
3. At the same time must be studied the saline infusion before the heat exchanged and separation before reinfusion in the body, with all necessary controls.
4. It is necessary to have a Technical medical team, specialized in many areas for:
Hematology studies Infectiologist for HIV virus and hepatities B.Biotechnological specialists.
PROJECT PLAN: PATIENT TREATMENTPROJECT PLAN: PATIENT TREATMENTWITH HIV AND HEPATITIES B VIRUSWITH HIV AND HEPATITIES B VIRUS
LUIS ANTONIO DA SILVA
PROJECT PLAN: PATIENT TREATMENTPROJECT PLAN: PATIENT TREATMENTWITH HIV AND HEPATITIES B VIRUSWITH HIV AND HEPATITIES B VIRUS
LUIS ANTONIO DA SILVA
CONCLUSION UP DATECONCLUSION UP DATE
1- This propose to HIV was denied due the major Virus quantity is not located in the blood
2- HOWEVER THIS TREATMENT CAN BE DONE TO : Pathologics Bacterias and Others Virus remainded in the BLOOD
3- The possibility of sucess over the others desease can be achieve with this propose.
PROJECT PLAN: PATIENT TREATMENTPROJECT PLAN: PATIENT TREATMENTWITH HIV AND HEPATITIES B VIRUSWITH HIV AND HEPATITIES B VIRUS
LUIS ANTONIO DA SILVA
OFFICIAL DOCUMEOFFICIAL DOCUMENT PNT PROVIDED ROVIDED TO Luis TO Luis Antonio da Silva fromAntonio da Silva from::
UNIVERSIDADE ESTADUAL DE CAMPINAS ( Brasil ),
AFTER THE EXPOSITIONOF THIS SUBJECT, REGARDING THE SEVERAL VIABILITIES USES OF THIS
MATTER .
PROJECT PLAN: PATIENT TREATMENTPROJECT PLAN: PATIENT TREATMENTWITH HIV AND HEPATITIES B VIRUSWITH HIV AND HEPATITIES B VIRUS
LUIS ANTONIO DA SILVA
Approved by Universidade de CampinasApproved by Universidade de Campinas
PROJECT PLAN: PATIENT TREATMENTPROJECT PLAN: PATIENT TREATMENTWITH HIV AND HEPATITIES B VIRUSWITH HIV AND HEPATITIES B VIRUS
LUIS ANTONIO DA SILVA
Approved by Universidade de CampinasApproved by Universidade de Campinas
PROJECT PLAN: PATIENT TREATMENTPROJECT PLAN: PATIENT TREATMENTWITH HIV AND HEPATITIES B VIRUSWITH HIV AND HEPATITIES B VIRUS
LUIS ANTONIO DA SILVA
THE AUTHOR IS OPEN TO A SPONSOR TO DO THE AUTHOR IS OPEN TO A SPONSOR TO DO THIS PROJETC.THIS PROJETC.
AUTHOR: Luis Antonio da SilvaMail : [email protected] : http://br.linkedin.com/in/luissilvamanagementPhone mobil : + 55 62 99178508
Top Related